消化

订阅

MedSci主页 / 所有栏目 / 消化

2019 AACR：MultiTAA T细胞疗法治疗胰腺癌

2019-07-22 Allan MedSci原创

MultiTAAT细胞疗法胰腺癌生存率
关注

Marker Therapeutics是一家临床阶段免疫肿瘤学公司，专门开发用于治疗血液系统恶性肿瘤和实体肿瘤的下一代T细胞免疫疗法，Marker Therapeutics近日公布了其正在进行的中期试验数据以评估MultiTAA T细胞疗法治疗胰腺癌的有效性。

Marker Therapeutics是一家临床阶段免疫肿瘤学公司，专门开发用于治疗血液系统恶性肿瘤和实体肿瘤的下一代T细胞免疫疗法，Marker Therapeutics近日公布了其正在进行的中期试验数据以评估MultiTAA T细胞疗法治疗胰腺癌的有效性。

该试验的首席研究员Brandon G. Smaglo博士说：“胰腺癌仍然是治疗中最具挑战性的实体恶性肿瘤之一，40多年来患者的生存率没有得到显著改善。我们对这些数据感到鼓舞，这些数据表明，当与标准化疗相结合时，MultiTAA T细胞疗法可能有助于更持久的治疗反应，MultiTAA T细胞疗法或可作为难治性患者的二线疗法”。


原始出处：

http://www.firstwordpharma.com/node/1654107#axzz5uMUC8wcD

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1400440, encodeId=68a814004402e, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478019, encodeId=270e14e8019f5, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551996, encodeId=32e31551996f7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-24 10518094zz

    #ACR#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1400440, encodeId=68a814004402e, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478019, encodeId=270e14e8019f5, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551996, encodeId=32e31551996f7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-24 124984edm24暂无昵称

    #T细胞疗法#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1400440, encodeId=68a814004402e, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478019, encodeId=270e14e8019f5, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551996, encodeId=32e31551996f7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Wed Jul 24 00:35:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-24 Luyuxie_14

    #AACR#

    0